TABLE 3.

Votes on Other Benefits and Contextual Considerations for Nadofaragene Firadenovec and Oportuzumab Monatox

1 (suggests lower value)	2 (intermediate)	3 (suggests higher value)
This intervention will not differentially benefit a historically disadvantaged or underserved community	6 votes	This intervention will differentially benefit a historically disadvantaged or underserved community
5 votes		0 votes
1 (suggests lower value)	2 (intermediate)	3 (suggests higher value)
Small health loss without this treatment as measured by absolute QALY shortfall	4 votes	Substantial health loss without this treatment as measured by absolute QALY shortfall
4 votes		3 votes
1 (suggests lower value)	2 (intermediate)	3 (suggests higher value)
Small health loss without this treatment as measured by proportional QALY shortfall	7 votes	Substantial health loss without this treatment as measured by proportional QALY shortfall
1 vote		3 votes
1 (suggests lower value)	2 (intermediate)	3 (suggests higher value)
Will not have a significant impact on improving return to work and/or overall productivity vs the comparator	7 votes	Will have a significant impact on improving return to work and/or overall productivity vs the comparator
3 votes		1 vote

QALY = quality-adjusted life-year.